We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Gyn4.5
Gynostemma Research
Too few graded studies
16 peer-reviewed studies
What the evidence says
Too few graded studies
Gynostemma doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2006–2026 with a typical study size of 16 participants.
Based on 16 studies · 1 meta-analysis · 9 RCTs · 16 total participants
In plain English: The findings presented may establish a foundation for subsequent clinical trials for the development of specific gypenosides as antidiabetic therapies for the betterment of human health.
Lee YZ, Kow ASF, Lee QL, Lim LWC, Yusof R, Tham CL, Ho YC, Lee MT. · Naunyn-Schmiedeberg's archives of pharmacology (2025)
Gypenosides can modulate various key pathways associated with diabetes pathogenesis, including PI3K/Akt, PPARγ, NF-κB, AMPK and PDX1, hence contributing to their antidiabetic properties.
Nevertheless, there is a paucity of research on gypenosides in clinical settings, with existing studies being mainly conducted on animal models and in vitro.
Future studies with the focus on the isolation and purification of specific gypenosides, as well as the exploration on the probable pharmacological effect and molecular mechanisms behind the biological actions are necessary.
In plain English: We examine the current research limitations and prospective directions for Gyps as potential therapeutic drugs or functional supplements.
Li X, Chen Y, Wang R, Cao B, Deng T, Han J, Yang M. · Frontiers in pharmacology (2025)
In the past 2 decades, a growing body of evidence has demonstrated that Gyps are crucial for the regulation of metabolic homeostasis, the reduction of oxidative stress and inflammation, the protection of the cardiovascular and hepatic systems, and the exhibition of anti-cancer potential.
However, obstacles such as limited oral bioavailability, a lack of standardized extracts, and insufficient clinical data restrict the translational potential of Gyps.
Recent developments in the pharmacological effects of Gyps, such as the biological characteristics of Gynostemma pentaphyllum and the pharmacokinetic and toxicological properties of Gyps, are summarized in this review.
In plain English: It is anticipated that these theoretical foundations will provide a useful reference for the future development and application of natural polysaccharides in functional foods and pharmaceuticals.
Hu X, Wang W, Zhang D, Tian X, Zhang A, Xu J, Feng F, Li W, Kikuchi T, Zhang J. · International journal of biological macromolecules (2025)
In recent decades, Gynostemma pentaphyllum polysaccharides (GPP) have been widely studied for their various health benefits and potential economic value.
However, there are relatively few reviews documenting these GPP.
Therefore, this paper reviews the research progress of GPP in terms of their sources, isolation and purification, structural characterization, bioactivity, conformational relationships, and applications.
In plain English: Future studies focusing on isolating and purifying novel gypenosides and investigations on exploring the potential molecular mechanism underlying their biological activities are warranted, which may serve as a foundation for further clinical trials for the betterment of human health.
Liang G, Lee YZ, Kow ASF, Lee QL, Cheng Lim LW, Yusof R, Tham CL, Ho YC, Lee MT. · European journal of pharmacology (2024)
To date, preclinical studies have demonstrated the therapeutic effects of gypenosides in alleviating neuropsychiatric disorders like depression, Parkinson's disease, Alzheimer's disease, secondary dementia, stroke, optic neuritis, etc.
Pharmacological studies have discovered that gypenosides can modulate various major signaling pathways like NF-κB, Nrf2, AKT, ERK1/2, contributing to the neuroprotective properties.
However, there is a dearth of clinical research on gypenosides, with current investigations on the compounds being mainly conducted in vitro and on animals.
In plain English: A small meta-analysis (15 studies) reported Gynostemma lowers triglycerides and raises HDL cholesterol; the paper is mostly preclinical (HFD mice + metabolomics).
Li Y et al. · Am J Chin Med (2023)
Pooled analysis: lower triglycerides, higher HDL cholesterol
Small (15-study) meta-analysis; human-only effect size not specified
Embedded in a mostly-preclinical paper (mouse mechanism: gut microbiota / tryptophan)
In plain English: This prematurely terminated pilot trial was severely underpowered and did not meet the pRNFL primary endpoint.
Lu Y et al. · Multiple sclerosis and related disorders (2026)
At 6 months, adjusted between-group differences were +16.2 μm for pRNFL thickness (95% CI -16.3 to 48.6; P = 0.274) and +0.034 mm³ for total macular volume (95% CI -0.166 to 0.234; P = 0.696).
Exploratory mGCIPL change showed a nominal difference (+18.0 μm, 95% CI 7.8 to 28.3; nominal P = 0.004), without consistent functional benefit.
This prematurely terminated pilot trial was severely underpowered and did not meet the pRNFL primary endpoint.
In plain English: A small crossover RCT (n=16) found Gynostemma (450mg) improved exercise performance and altered mitochondrial markers in healthy untrained males.
Nayyar D et al. · Nutrients (2023)
Improved exercise performance and mitochondrial markers